Joel Hay

22101 Dardenne St.
Calabasas, CA 91302
Email: Jhay@usc.edu
Web: www.pharmerit.com

Joel W. Hay is Associate Professor and Founding Chair in the Department of Pharmaceutical Economics and Policy in the School of Pharmacy, with a joint appointment in the Department of Economics at the University of Southern California.  He also serves as the USC Project Coordinator for the Rand Evidence-Based Medicine Practice Centers of Southern California funded by the US Agency for Health Research and Quality, and Co-Investigator at the USC Alzheimer Research Center funded by the California Dept. of Health Services.  He is a Health Economics Research Scholar at the UCLA Center for Vaccine Research. He is a founding Executive Board member of the American Society for Health Economics, and a member of the Scientific Advisory Board for the Disease Management Association of America.  He is also Scientific Director for Pharmerit, North America.  

Dr. Hay has prepared expert reports and depositions in a number of legal cases, primarily relating to economic assessment of pharmaceutical value and/or pharmaceutical market damages.  He has experience with several cases relating to pharmaceutical intellectual property disputes and damage assessment.
 His previous positions include: Senior Research Fellow, the Hoover Institution, Stanford University (1985-1992); Senior Policy Analyst, Project HOPE (1983-1985); Asst. Professor, Dept. of Behavioral Sciences and Community Health, and Dept. of Economics, University of Connecticut (1980-1984); and Asst. Research Professor, University of Southern California (1978-1980). .  He received his B.A. summa cum laude from Amherst College in 1974 and his M.A. (1975), M. Ph. (1976) and Ph.D. in economics (1980) from Yale University.

Dr. Hay has authored or coauthored over 100 peer-reviewed scientific articles in the fields of health economics, outcomes research, disease management, statistics, econometrics, epidemiology and health care in journals including: Am J Cardiology, Am J Health-Systems Pharmacy, Am J Managed Care, Am J Public Heath, Arch Neurology, Haemophilia, Health Care Financing Review, Health Policy, JAMA, J AIDS, J Am Geriatrics Society, J Business & Economic Statistics, J Clinical Gastroenterology, J Health Economics, J Health Politics, Policy and Law, J Human Resources, J Royal Statistical Assoc, Medical Care, Pediatrics, Value in Health.   

Dr. Hay has served as a consultant to U.S. Centers for Medicare and Medicaid Services, U.S. Agency for Healthcare Research and Quality, U.S. Centers for Disease Control and Prevention, U.S. Public Health Service, U.S. Food and Drug Administration, U.S. Environmental Protection Agency, Government of Hungary, Hong Kong Centre for Economic Research, Hong Kong Medical Executives Association, World Bank, California AIDS Commission, California Medi-Cal Drug Advisory Board, County of San Diego Medically Indigent Adult program, and County of Sacramento Homeless Program.  Dr. Hay has also written numerous health-related op-eds published in papers such as Los Angeles Times, Wall Street Journal, San Francisco Chronicle, San Diego Union, Sacramento Bee and Newsday.

Dr. Hay has served as a Member of the Expert Advisory Panel on Drug Utilization Review, United States Pharmacopeial Convention; an Executive Committee member for the federally-sponsored Southern California Evidence-Based Medicine Practice Center; and a member of the JAMA Web Site HIV/AIDS Editorial Review Panel.  Dr. Hay is a founding member of the Board of Directors of the International Society for Pharmacoeconomics and Outcomes Research.  He is founding Editor-in-Chief of Value in Health, the Journal of the International Society for Pharmacoeconomics and Outcomes Research.  He has recently completed a study of hospital and pharmaceutical costs for the national Blue Cross Blue Shield Association (http://bcbshealthissues.com/costpressconf/materials.vtml).  This report has been discussed in several national media, including NPR, CSPAN, USA Today, US News and World Report and others.

pharmaceutical economics, health economics, pharmaceutical and medical device intellectual property, health care market damages, health care patient damage assessments